Special Issue

Cystic Fibrosis: Therapy and Genetics

Message from the Guest Editors

Cystic fibrosis (CF) is the most common monogenic fatal disorder in the Caucasian population caused by recessive mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR). Affects multiple organs but lung failure is responsible for the most CF-related morbidity and mortality. CF is a complex disease, but research has led to various treatments including pancreatic enzyme replacement therapy and infection control to help patients to cope with disease symptoms. CFTR protein is a cyclic AMP-dependent ion channel and mutations that affect its function or dramatically reduce its expression level has led to defects in ion transport in multiple epithelial organs. Recent efforts in developing drugs for CFTR-targeting has provided proof that the concept of treating the cause of the disease is a better strategy. In addition, for those patients whose mutations cause no CFTR protein expression, these new drugs will not work for them. Therefore, more research is needed to develop better or more effective treatments. Gene therapy has long been sought as a novel approach to directly treat CF lung disease.

Guest Editors

Prof. Dr. Jim Hu

Prof. Dr. Uta Griesenbach

Prof. Dr. Joseph Zabner

Deadline for manuscript submissions

closed (4 February 2019)

GCAT
TACG
GCAT

Genes

an Open Access Journal by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed

mdpi.com/si/16104

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

mdpi.com/journal/genes

MDPI

GCAT
TACG
GCAT

Genes

an Open Access Journal by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed

mdpi.com/journal/genes

MDPI

About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Department of Pathology, The University of Alabama at Birmingham, 1825 University Blvd, SHEL 814, Birmingham, AL 35294-2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))